Close Menu

Enpicom ImmunoGenomiX Software V2.0

Apr 01, 2020

Dutch bioinformatics firm Enpicom has released version 2.0 of its ImmunoGenomiX (IGX) Platform for the management, analysis, and visualization of T- and B-cell receptor sequencing data. The new version supports single-cell sequencing data in addition to bulk sequencing data. The ability to analyze data from both single-cell and bulk sequencing workflows in tandem provides new opportunities for immunomics research and drug development, the company said. Other new enhancements include the IGX-Compare app, which allows users to compare any two data sets to visualize and prioritize matching clones; and more extensive data support, supporting the upload of readily annotated clone tables from, for instance, 10x Genomics or Adaptive Biotechnologies. The new version also features more clonotype grouping definitions and V/J gene usage plotting.

More Like This

Sep 17, 2020

Sanford Burnham Prebys Coronascape Bioinformatics Platform

Sanford Burnham Prebys Medical Discovery Institute has introduced Coronascape, a specialized version of its Metascape bioinformatics platform designed for big-data analysis of SARS-CoV-2 and COVID-19 research. The La Jolla, California-based research institute said that Coronascape is meant to serve as a multiomics data clearinghouse for efforts to develop effective targets and therapies for the novel coronavirus. SBP developed the web-based Metascape portal in partnership with the Genomics Institute of the Novartis Research Foundation and the University of California, San Diego.

Sep 15, 2020

10x Genomics Chromium Single-Cell Multiome ATAC + Gene Expression

10x Genomics has launched its Chromium Single-Cell Multiome ATAC + Gene Expression solution.

Combining the assay for transposase-accessible chromatin using sequencing with gene expression profiling by RNA sequencing, the new product enables researchers to analyze both epigenetic programming and the transcriptome in the same cell.

Sep 15, 2020

Paradigm4 Reveal: Single Cell

Paradigm4 has introduced Reveal: Single Cell, an app to help biopharmaceutical companies manage and analyze large sets of single-cell data. Reveal: Single Cell, built on top of the bioinformatics firm's SciDB database management platform, supports multiomic analysis and association. Paradigm4 said that users can choose cells across multiple studies to evaluate tissue distribution, look for variance in response to treatment, and compare normal to diseased cells. The new app is an extension of Reveal, a translational informatics platform released in 2018.

Sep 14, 2020

Bianano Genomics Lineagen EpiPanel Dx Plus

Bionano Genomics' recent acquisition Lineagen has launched the EpiPanel Dx Plus, a laboratory developed test for epilepsy-related conditions.

The proprietary gene panel is based on 223 genes selected from a literature review, including genes with pathogenic variants identified in more than 2,000 epileptic patients tested by Lineagen.

The test is designed for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures and can predict the recurrence risk for other members of the family and allows for personalized treatment.

It has an expected diagnostic yield of 30 percent.

Sep 10, 2020

NimaGen SARS-CoV-2 WGS Kit

NimaGen of Nijmegen, the Netherlands, has launched the EasySeq SARS-CoV-2 Whole Genome Sequencing Kit. It is based on a patented reverse complement PCR (RC-PCR) library preparation method that combines target amplification and indexing into a single closed-tube PCR step, reducing hands-on time and risk of cross contamination or sample mix up. The kit includes tiled RC-PCR primer and probe pools to cover 99 percent of the viral genome with more than 90 percent read uniformity. Also included are the RC-PCR mastermix, UDI indexes, and an AmpliClean Magnetic Bead Clean-up kit.

Sep 09, 2020

CRG COVID-19 Viral Beacon Platform

The Center for Genomic Regulation (CRG) in Barcelona has launched COVID-19 Viral Beacon, a platform that lets scientists analyze raw and consensus COVID-19 genomic data from the European Nucleotide Archive (ENA), Oxford Nanopore Technologies, Illumina, NCBI/SRA, and GISAID. Users can search for specific genetic variants and explore associated metadata.

Sep 04, 2020

Combinati Q SARS-CoV-2 Triple Assay for Absolute Q Digital PCR System

Combinati has launched the Q SARS-CoV-2 Triplex Assay for its Absolute Q digital PCR system. The multiplexed, research-use-only assay detects SARS-CoV-2 nucleic acids from extracted samples in a single reaction. The workflow includes microfluidic array partitioning plates and required reagents, has one hands-on step, and provides results in 90 minutes. The assay demonstrates sensitivity down to single viral targets, enabling researchers to detect trace amounts of virus even in a high background of human genomic DNA, according to the company.

Sep 03, 2020

Emedgene Automated CNV Classification

Emedgene has added automatic classification of copy-number variants to its genomic interpretation platform, following 2020 American College of Medical Genomics (ACMG) and Clinical Genome Resource (ClinGen) guidelines. The Israeli vendor said that the new informatics tool cuts classification time by as much as 90 percent for variants that do not require literature curation and 50 percent for those that do. 

Sep 03, 2020

Yourgene Iona Nx Noninvasive Prenatal Test

Yourgene this week launched the Iona Nx Noninvasive Prenatal Test (NIPT) after having applied CE marking in June. Iona Nx is designed to run on Illumina's NextSeq 550 Dx next-generation sequencing platform, and uses the Yourgene SP150 and Yourgene QS250 instruments to combine DNA extraction, sample preparation, and enrichment ahead of the sequencing step. The QS250 is powered by Ranger technology from Coastal Genomics, which Yourgene acquired recently acquired, and features a step that enriches fetal fraction two-fold, reducing the amount of sequencing necessary and decreasing cost. The assay has greater than 99.99 percent accuracy, according to the company, and features whole-genome analysis including for trisomy 21, 18, and 13; sex chromosomal aneuploidies; other autosomal aneuploidies; and optional fetal sex determination. It will also feature microdeletion analysis in the future, the company said.

Yourgene will initially transition existing customers to the new assay in the UK and France, followed by other European territories. 

Sep 02, 2020

Castle Biosciences DecisionDx-SCC

Castle Biosciences has launched DecisionDx-SCC, its prognostic gene expression profile test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC). DecisionDx-SCC is a qRT-PCR assay of 40 genes that uses a neural network algorithm to classify individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors. The test result, in which patients are stratified into a Class 1, 2A, or 2B risk category, predicts individual metastatic risk to inform risk-appropriate management.

Sep 02, 2020

Promega Spectrum Compact CE System

Promega has launched the Spectrum Compact CE system, a benchtop capillary electrophoresis instrument for Sanger sequencing and DNA fragment analysis it developed in collaboration with Hitachi High-Tech. The platform, first announced in 2017, can process up to 32 samples in a single run and supports applications such as microsatellite instability analysis, mixed sample analysis, forensic STR analysis, and cell line authentication.

Sep 02, 2020

Agilent SureSelect XT HS2 RNA Reagent Kit

Agilent has launched its SureSelect XT HS2 RNA Reagent Kit. The kit offers a modular design that provides a simple and parallel approach for both RNA and DNA samples, which the firm noted will help customers streamline and combine workflows without losing time optimizing different kits for different sample types.

Agilent's kit will allow customers to accurately profile gene expression and detect RNA fusions using low-input formalin-fixed paraffin-embedded samples. The kit supports 384 unique dual sample indexes and helps customers to multiplex hundreds of samples in a single sequencing run without worrying about index hopping, the firm said. The kit also features molecular barcodes for more efficient de-duplication of sequencing reads and more accurate gene expression analysis.

Sep 02, 2020

BioReference Laboratories OnKoSight Advanced

Opko Health's BioReference Laboratories announced the launch of its next-generation sequencing assay OnKoSight Advanced, which enables DNA mutational profiling of tumor samples. The test, developed by BioReference's specialty oncology division GenPath, offers targeted gene content aligned with recent National Comprehensive Cancer Network and World Health Organization guidelines. The panels include key biomarkers, such as tumor mutation burden and tumor-only microsatellite, and are tumor-type specific. They are also "optimized to exclude extraneous gene content," the company said.  

Aug 27, 2020

RareCyte Arv7/Synaptophysin Panel Kit

RareCyte's Arv7/Synaptophysin Panel Kit is a research-use-only dual-biomarker liquid biopsy assay for androgen receptor splice variant 7 (Arv7) and the neuroendocrine marker synaptophysin (SYP) that enables customers to evaluate the expression of both biomarkers on circulating tumor cells from prostate cancer patients. The assay comprises processing blood to slides with the AccuCyte Sample Preparation System followed by staining with the ARv7/Synaptophysin kit and imaging on a CyteFinder instrument. Machine learning-enabled analysis and scoring maximizes reviewer concordance. In addition, the RareCyte platform enables cell-free DNA analysis on the same sample, providing a comprehensive liquid biopsy assessment of tumor status, the company said.

Aug 25, 2020

M2Gen Oncology-Focused Bioinformatics Support Services

M2Gen has launched oncology-focused bioinformatics support services. Leveraging the results and knowledge gained from the Orien Avatar Program, an oncology clinic-genomics dataset, M2Gen offers bioinformatics services that include paired tumor and germline whole-exome sequencing (WES) analysis with panels-of-normal filtering; tumor-only WES analysis with virtual-normal somatic mutation classification; and tumor-only RNA sequencing analysis. M2Gen said that pipeline analysis is WES and RNA-seq capture kit-agnostic, and uses the most up-to-date human genome reference and gene build.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
26
Sponsored by
Sophia Genetics

This webinar will discuss Genotypos Science Labs’ experience with a whole-exome sequencing solution supporting the detection of copy number variants (CNVs) for the management of complex cases.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.